The genome and epigenome of malignant melanoma
- PMID: 18042149
- DOI: 10.1111/j.1600-0463.2007.apm_855.xml.x
The genome and epigenome of malignant melanoma
Abstract
Malignant melanoma originates in melanocytes, the pigment-producing cells of the skin and eye, and is one of the most deadly human cancers with no effective cure for metastatic disease. Like many other cancers, melanoma has both environmental and genetic components. For more than 20 years, the melanoma genome has been subject to extensive scrutiny, which has led to the identification of several genes that contribute to melanoma genesis and progression. Three molecular pathways have been found to be nearly invariably dysregulated in melanocytic tumors, including the RAS-RAF-MEK-ERK pathway (through mutation of BRAF, NRAS or KIT), the p16 INK4A-CDK4-RB pathway (through mutation of INK4A or CDK4) and the ARF-p53 pathway (through mutation of ARF or TP53). Less frequently targeted pathways include the PI3K-AKT pathway (through mutation of NRAS, PTEN or PIK3CA) and the canonical Wnt signaling pathway (through mutation of CTNNB1 or APC). Beyond the specific and well-characterized genetic events leading to activation of proto-oncogenes or inactivation of tumor suppressor genes in these pathways, systematic high-resolution genomic analysis of melanoma specimens has revealed recurrent DNA copy number aberrations as well as perturbations of DNA methylation patterns. Melanoma provides one of the best examples of how genomic analysis can lead to a better understanding of tumor biology. We review current knowledge of the genes involved in the development of melanoma and the molecular pathways in which these genes operate.
Similar articles
-
KIT pathway alterations in mucosal melanomas of the vulva and other sites.Clin Cancer Res. 2011 Jun 15;17(12):3933-42. doi: 10.1158/1078-0432.CCR-10-2917. Clin Cancer Res. 2011. PMID: 21680547
-
Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.Oncol Rep. 2005 Dec;14(6):1481-5. Oncol Rep. 2005. PMID: 16273242
-
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.Cancer Res. 2004 Aug 15;64(16):5556-9. doi: 10.1158/0008-5472.CAN-04-1669. Cancer Res. 2004. PMID: 15313890
-
MicroRNAs in the pathogenesis of malignant melanoma.J Eur Acad Dermatol Venereol. 2013 Feb;27(2):142-50. doi: 10.1111/j.1468-3083.2012.04579.x. Epub 2012 May 23. J Eur Acad Dermatol Venereol. 2013. PMID: 22621697 Review.
-
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. J Cell Physiol. 2011. PMID: 21302297 Review.
Cited by
-
The mTOR signalling pathway in human cancer.Int J Mol Sci. 2012;13(2):1886-1918. doi: 10.3390/ijms13021886. Epub 2012 Feb 10. Int J Mol Sci. 2012. PMID: 22408430 Free PMC article. Review.
-
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Aging (Albany NY). 2011 Mar;3(3):192-222. doi: 10.18632/aging.100296. Aging (Albany NY). 2011. PMID: 21422497 Free PMC article. Review.
-
Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus.Oncotarget. 2014 Aug 15;5(15):5893-907. doi: 10.18632/oncotarget.1839. Oncotarget. 2014. PMID: 25071017 Free PMC article.
-
CTGF is a therapeutic target for metastatic melanoma.Oncogene. 2014 Feb 27;33(9):1093-100. doi: 10.1038/onc.2013.47. Epub 2013 Feb 25. Oncogene. 2014. PMID: 23435419 Free PMC article.
-
The stable traits of melanoma genetics: an alternate approach to target discovery.BMC Genomics. 2012 Apr 26;13:156. doi: 10.1186/1471-2164-13-156. BMC Genomics. 2012. PMID: 22537248 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous